Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Author
Coyle, L; Morley, NJ; Rambaldi, A; Mason, KD; Verhoef, G; Furness, CL; Zhang, A; Jung, AS; Cohan, D; Franklin, JLDate
2020-05-31Source Title
Leukemia and LymphomaPublisher
TAYLOR & FRANCIS LTDUniversity of Melbourne Author/s
Mason, KylieAffiliation
Sir Peter MacCallum Department of OncologyMetadata
Show full item recordDocument Type
Journal ArticleCitations
Coyle, L., Morley, N. J., Rambaldi, A., Mason, K. D., Verhoef, G., Furness, C. L., Zhang, A., Jung, A. S., Cohan, D. & Franklin, J. L. (2020). Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 61 (9), pp.2103-2112. https://doi.org/10.1080/10428194.2020.1759055.Access Status
Access this item via the Open Access locationOpen Access URL
http://doi.org/10.1080/10428194.2020.1759055Abstract
The phase 2 portion of this open-label phase 2/3 study assessed the efficacy and safety of blinatumomab as second salvage for aggressive relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) following platinum-based first salvage chemotherapy. Forty-one patients with aggressive disease (32% relapsed; 68% refractory) enrolled and received stepwise blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2; 19 (46%) completed cycle 1 and 3 (7%) completed cycle 2. The overall response rate after 12 weeks was 37%, including 9 (22%) complete metabolic responses. Eight (20%) patients (all responders) subsequently received stem cell transplants. Grade ≥3 adverse events were reported in 29 (71%) patients. Grade 3 cytokine release syndrome occurred in one patient. Grade 3 neurologic events occurred in 10 (24%) patients; all resolved. Blinatumomab monotherapy appears effective as second salvage therapy in patients with r/r aggressive B-NHL. Trial registration: NCT02910063.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References